Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIRT1 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Intrathecal
01
Overview
SIRT1 siRNA is a research-use small interfering RNA (siRNA) reagent designed to silence the expression of the SIRT1 gene (Sirtuin 1) via RNA interference (RNAi). SIRT1 is an NAD+-dependent protein deacetylase (class III histone deacetylase) that plays a critical role in regulating cellular processes such as apoptosis, senescence, glucose homeostasis, and aging. In various malignancies, including pancreatic adenocarcinoma, prostate cancer, and breast cancer, SIRT1 is frequently overexpressed and contributes to tumor progression by repressing tumor suppressor genes. Knockdown of SIRT1 using specific siRNA duplexes has been shown in preclinical research to induce growth arrest and apoptosis in cancer cell lines. This reagent is primarily utilized as a laboratory tool for functional genomics and is not currently developed as a proprietary clinical therapeutic asset.
- Other names
- Sirtuin 1 siRNASirtuin1 siRNASirtuin-1 siRNASirt1 small interfering RNASirt-1 small interfering RNASirt 1 small interfering RNASignalSilence SirT1 siRNA I
02
Targets
SIRT1 (NAD-dependent protein deacetylase sirtuin-1)
Beyond the preview
Go deeper on SIRT1 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIRT1 siRNA.